Menu
Not yet recruiting NCT07709429

Qigong Exercise for Muscles Strength and Quality of Life in Colorectal Cancer Patients Undergoing Chemotherapy

No phase Interventional Colorectal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Qigong Exercise, Conventional Exercise Program.
Who it may be relevant to
Registry conditions: Colorectal Cancer. Basic parameters: 35 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this study is to evaluate therapeutic effect of Qigong for muscle strength and quality of life in colorectal cancer patients undergoing chemotherapy.

Detailed description

Muscle weakness and fatigue are prevalent side effects experienced by patients undergoing chemotherapy for colorectal cancer. These symptoms can significantly impact daily functioning and overall quality of life. Finding effective treatments for this condition is crucial to improving patient outcomes and quality of life.

Qigong serves as a holistic exercise modality that not only strengthens muscles but also elevates the overall quality of life. Its gentle movements make it accessible to a wide range of individuals, including those undergoing rehabilitation or managing chronic health issues.

Furthermore the need of this study is developed from lack in the quantitative knowledge and information in the published studies about the effect of Qigong on muscle strength and quality of life in colorectal cancer patients undergoing chemotherapy.

Interventions

  • Other Qigong Exercise
    Participants will receive a supervised Baduanjin Qigong exercise program combined with conventional exercises, including pain-free range-of-motion exercises, low-intensity walking, and physical therapy education. The intervention will be conducted three times weekly for 12 weeks under physiotherapist supervision, while participants continue their prescribed chemotherapy and routine medical follow-up.
  • Other Conventional Exercise Program
    Participants in this arm will receive a conventional exercise program consisting of pain-free range-of-motion exercises for the shoulder, elbow, wrist, hip, knee, and ankle joints, low-intensity walking, and physical therapy education to maintain daily activities. The intervention will be administered for 12 weeks, with three sessions per week. Participants will continue their prescribed chemotherapy and routine outpatient medical follow-up throughout the study and will not participate in any ad

Primary outcome measures

  • Muscle Strength [Time frame: 12 weeks]
Secondary outcome measures (1)
  • Health-Related Quality of Life [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • Age ranges between 35 and 55 years.
  • Male \& female patients will participate in the study.
  • All patients with colorectal cancer undergoing chemotherapy.
  • All patients enrolled to the study will have their informed consent.
  • The patients will be instructed to report any side effects during the management.

Exclusion criteria

  • Presence Patients with psychological disturbance or mental illness.
  • Cardiopulmonary disease.
  • Hypotensive patients.
  • Nerve, muscle, or joint disease, or other malignant tumors affecting movement.
  • Autoimmune disease.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Faculty of Physical Therapy, Cairo University — Giza

Identifiers

NCT: NCT07709429 · P.T.REC/012/005843

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗